For millions of Americans living with advanced cancer, access to comprehensive genomic profiling is not an abstract policy question. It is the critical first step toward identifying whether a targeted therapy may extend or save their life. ACGP shares CMS’s commitment to eliminating fraud, waste, and abuse, and we firmly believe this goal can be achieved without undermining the remarkable progress that precision oncology has made possible. Read the full letter below.
